Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors

Modlin, 2008, Gastroenteropancreatic neuroendocrine tumours, Lancet Oncol, 9, 61, 10.1016/S1470-2045(07)70410-2

Papotti, 2002, Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis, Virchows Arch, 440, 461, 10.1007/s00428-002-0609-x

Kulaksiz, 2002, Identification of somatostatin receptor subtypes 1, 2a, 3 and 5 in neuroendocrine tumours with subtype specific antibodies, Gut, 50, 52, 10.1136/gut.50.1.52

Korner, 2005, Value of immunohistochemistry for somatostatin receptor subtype sst2a in cancer tissues: Lessons from the comparison of anti-sst2a antibodies with somatostatin receptor autoradiography, Am J Surg Pathol, 29, 1642, 10.1097/01.pas.0000174013.14569.90

Zamora, 2010, Buenos Aires and La Plata Argentina Argentum Working Group: Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours, Dig Liver Dis, 42, 220, 10.1016/j.dld.2009.07.018

Volante, 2007, Somatostatin receptor type 2a immunohistochemistry in neuroendocrine tumors: A proposal of scoring system correlated with somatostatin receptor scintigraphy, Mod Pathol, 20, 1172, 10.1038/modpathol.3800954

Hofland, 2003, The pathophysiological consequences of somatostatin receptor internalization and resistance, Endocr Rev, 24, 28, 10.1210/er.2000-0001

Oberg, 2010, Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy, Gastroenterology, 139, 742, 10.1053/j.gastro.2010.07.002

Oberg, 2004, Future aspects of somatostatin-receptor-mediated therapy, Neuroendocrinology, 80, S57, 10.1159/000080743

Appetecchia, 2010, Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives, J Exp Clin Cancer Res, 29, 19, 10.1186/1756-9966-29-19

Rinke, 2009, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the promid study group, J Clin Oncol, 27, 4656, 10.1200/JCO.2009.22.8510

Caplin, 2014, Lanreotide in metastatic enteropancreatic neuroendocrine tumors, N Engl J Med, 371, 224, 10.1056/NEJMoa1316158

Lim, 2011, Gastroenteropancreatic neuroendocrine tumors: Incidence and treatment outcome in a single institution in korea, Asia Pac J Clin Oncol, 7, 293, 10.1111/j.1743-7563.2011.01423.x

Hauso, 2008, Neuroendocrine tumor epidemiology: Contrasting norway and north america, Cancer, 113, 2655, 10.1002/cncr.23883

Yao, 2008, One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states, J Clin Oncol, 26, 3063, 10.1200/JCO.2007.15.4377

Wang, 2012, Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995–2012) in south china, BMC Endocr Disord, 12, 30, 10.1186/1472-6823-12-30

Ito, 2013, Phase ii study of sunitinib in japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor, Invest New Drugs, 31, 1265, 10.1007/s10637-012-9910-y

Raymond, 2011, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors, N Engl J Med, 364, 501, 10.1056/NEJMoa1003825

Bosman, 2010, Who classification of tumours of the digestive system, 4th

Rindi, 2006, Tnm staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system, Virchows Arch, 449, 395, 10.1007/s00428-006-0250-1

Rindi, 2007, Tnm staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system, Virchows Arch, 451, 757, 10.1007/s00428-007-0452-1

Eisenhauer, 2009, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Chen, 2012, Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0, J Am Acad Dermatol, 67, 1025, 10.1016/j.jaad.2012.02.010

Diakatou, 2011, Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: An immunohistochemical study, Endocr Pathol, 22, 24, 10.1007/s12022-011-9149-8

van Adrichem, 2016, Is there an additional value of somatostatin receptor subtype 2a immunohistochemistry over somatostatin receptor scintigraphy uptake in predicting gastroenteropancreatic neuroendocrine tumor response?, Neuroendocrinology, 103, 560, 10.1159/000441604

Sclafani, 2011, Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: Clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors, Tumori, 97, 620, 10.1177/030089161109700514

Yerci, 2015, Somatostatin receptor 2 and 5 expressions in gastroenteropancreatic neuroendocrine tumors in turkey, Asian Pac J Cancer Prev, 16, 4377, 10.7314/APJCP.2015.16.10.4377

Nasir, 2006, Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: Immunohistochemical approach with potential clinical utility, Cancer Control, 13, 52, 10.1177/107327480601300108

Srirajaskanthan, 2009, Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies, Neuroendocrinology, 89, 308, 10.1159/000179899

Okuwaki, 2013, Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2a to outcomes, Cancer, 119, 4094, 10.1002/cncr.28341

Kaemmerer, 2015, Inverse expression of somatostatin and cxcr4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy, Oncotarget, 6, 27566, 10.18632/oncotarget.4491

Corleto, 2009, Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas, Neuroendocrinology, 89, 223, 10.1159/000167796

Jann, 2013, Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin, Neuroendocrinology, 98, 137, 10.1159/000353785

Broder, 2015, Gastrointestinal neuroendocrine tumors treated with high dose octreotide-lar: A systematic literature review, World J Gastroenterol, 21, 1945, 10.3748/wjg.v21.i6.1945

Welin, 2004, High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours, Eur J Endocrinol, 151, 107, 10.1530/eje.0.1510107

Ferolla, 2012, Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses, J Endocrinol Invest, 35, 326

Baldelli, 2014, Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: Current aspects and new perspectives, Front Endocrinol (Lausanne), 5, 7, 10.3389/fendo.2014.00007

Yao, 2011, Everolimus for advanced pancreatic neuroendocrine tumors, N Engl J Med, 364, 514, 10.1056/NEJMoa1009290

Kouvaraki, 2004, Fluorouracil, doxorubicin and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas, J Clin Oncol, 22, 4762, 10.1200/JCO.2004.04.024

Sun, 2005, Eastern Cooperative Oncology Group: Phase ii/iii study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern cooperative oncology group study e1281, J Clin Oncol, 23, 4897, 10.1200/JCO.2005.03.616